{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:20:25Z","timestamp":1790716825099,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11523-020-00758-2","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T13:04:20Z","timestamp":1603112660000},"page":"697-708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Targeting Nuclear Export Proteins in Multiple Myeloma Therapy"],"prefix":"10.1007","volume":"15","author":[{"given":"Nicholas","family":"Theodoropoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Lancman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"issue":"2","key":"758_CR1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.drudis.2019.11.008","volume":"25","author":"F Alanazi","year":"2020","unstructured":"Alanazi F, Kwa F, Burchall G, Jackson DE. New generation drugs for treatment of multiple myeloma. Drug Discov Today. 2020;25(2):367\u201379.","journal-title":"Drug Discov Today."},{"issue":"7","key":"758_CR2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373(7):621\u201331.","journal-title":"N Engl J Med."},{"issue":"9","key":"758_CR3","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell R, Lakshman A, Gahvari Z, McGehee E, Jagosky M, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375.","journal-title":"Leukemia"},{"issue":"8","key":"758_CR4","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","volume":"83","author":"JG Turner","year":"2020","unstructured":"Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2020;83(8):1021\u201332.","journal-title":"Biochem Pharmacol."},{"issue":"12","key":"758_CR5","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.18632\/oncotarget.1339","volume":"4","author":"ZL Huang","year":"2013","unstructured":"Huang ZL, Gao M, Li QY, Tao K, Xiao Q, Caso WX, et al. Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus. Oncotarget. 2013;4(12):2249\u201360.","journal-title":"Oncotarget."},{"issue":"2","key":"758_CR6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.celrep.2012.07.007","volume":"2","author":"B Culjkovic-Kraljacic","year":"2012","unstructured":"Culjkovic-Kraljacic B, Baguet A, Volpon L, Amri A, Borden K. The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation. Cell Rep. 2012;2(2):207\u201315.","journal-title":"Cell Rep."},{"issue":"4","key":"758_CR7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s12032-013-0726-1","volume":"30","author":"F Zhou","year":"2013","unstructured":"Zhou F, Qiu W, Yao R, Xiang J, Sun X, Liu S, et al. CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas. Med Oncol. 2013;30(4):726.","journal-title":"Med Oncol."},{"issue":"20","key":"758_CR8","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood-2012-08-447581","volume":"121","author":"K Kojima","year":"2013","unstructured":"Kojima K, Kornblau S, Ruvolo V, Dilip A, Dubburi S, Davis R, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013;121(20):4166\u201374.","journal-title":"Blood"},{"issue":"5","key":"758_CR9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","volume":"18","author":"UH Gandhi","year":"2018","unstructured":"Gandhi UH, Senapedis W, Baloglu E, Unger T, Chari A, Vagl D, et al. Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. Clin Lymph Myeloma Leuk. 2018;18(5):335\u201345.","journal-title":"Clin Lymph Myeloma Leuk."},{"issue":"12","key":"758_CR10","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","volume":"27","author":"J Schmidt","year":"2013","unstructured":"Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Xin CS, et al. Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia. 2013;27(12):2357\u201365.","journal-title":"Leukemia"},{"issue":"1","key":"758_CR11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-017-0412-4","volume":"10","author":"V Camus","year":"2017","unstructured":"Camus V, Miloudi H, Taly A, Sola B, Jardin F. XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J Hematol Oncol. 2017;10(1):47.","journal-title":"J Hematol Oncol."},{"key":"758_CR12","doi-asserted-by":"crossref","first-page":"103504","DOI":"10.1016\/j.jprot.2019.103504","volume":"209","author":"V Chanukuppa","year":"2019","unstructured":"Chanukuppa V, Paul D, Taunk K, Chatterjee T, Sharma S, Kumar S, et al. XPO1 is a critical player for bortezomib resistance in multiple myeloma: a quantitative proteomic approach. J Proteom. 2019;209:103504.","journal-title":"J Proteom."},{"key":"758_CR13","unstructured":"US FDA. FDA grants accelerated approval to selinexor for multiple myeloma. 2019. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-selinexor-multiple-myeloma. Accessed 15 Sept 2020."},{"issue":"6","key":"758_CR14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.7164\/antibiotics.36.646","volume":"36","author":"T Hamamoto","year":"1983","unstructured":"Hamamoto T, Seto H, Beppu T. Leptomycins A and B, new antifungal antibiotics II. Structure elucidation. J Antibiot (Tokyo). 1983;36(6):646\u201350.","journal-title":"J Antibiot (Tokyo)"},{"issue":"9","key":"758_CR15","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1016\/S0021-9258(17)37374-X","volume":"269","author":"K Nishi","year":"1994","unstructured":"Nishi K, Yoshida M, Fujiwara D, Nishikawa M, Horinouchi S, Beppu T. Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J Biol Chem. 1994;269(9):6320\u20134.","journal-title":"J Biol Chem."},{"issue":"16","key":"758_CR16","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1073\/pnas.96.16.9112","volume":"96","author":"N Kudo","year":"1999","unstructured":"Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner E, Wolff B, et al. Leptomycin B inactivates CRM1\/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA. 1999;96(16):9112\u20137.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"2","key":"758_CR17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00256156","volume":"16","author":"BJ Roberts","year":"1986","unstructured":"Roberts BJ, Hamelehle KL, Sebolt JS, Leopold WR. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother Pharmacol. 1986;16(2):95\u2013101.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"4","key":"758_CR18","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.1996.415","volume":"74","author":"ES Newlands","year":"1996","unstructured":"Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer. 1996;74(4):648\u20139.","journal-title":"Br J Cancer."},{"issue":"2\u20133","key":"758_CR19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00253-003-1300-0","volume":"62","author":"A Burzlaff","year":"2003","unstructured":"Burzlaff A, Kalesse M, Kasper C, Scheper T. Multi parameter in vitro testing of ratjadone using flow cytometry. Appl Microbiol Biotechnol. 2003;62(2\u20133):174\u20139.","journal-title":"Appl Microbiol Biotechnol."},{"issue":"17","key":"758_CR20","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1158\/0008-5472.CAN-09-0484","volume":"69","author":"JG Turner","year":"2009","unstructured":"Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, et al. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res. 2009;69(17):6899\u2013905.","journal-title":"Cancer Res."},{"issue":"11","key":"758_CR21","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00018-008-7452-4","volume":"65","author":"H Hatcher","year":"2008","unstructured":"Hatcher H, Planalp R, Cho J, Torti F, Torti S. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65(11):1631\u201352.","journal-title":"Cell Mol Life Sci."},{"issue":"10","key":"758_CR22","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/tra.12090","volume":"14","author":"N Mingshan","year":"2013","unstructured":"Mingshan N, Sinjin W, Yongliag Y. CRM1 is a cellular target of curcumin: new insights for the myriad of biological effects of an ancient spice. Traffic. 2013;14(10):1042\u201352.","journal-title":"Traffic."},{"issue":"7","key":"758_CR23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.5483\/BMBRep.2017.50.7.077","volume":"50","author":"EW Lee","year":"2017","unstructured":"Lee EW, Oh W, Song HP, Kim WK. Phosphorylation of p53 at threonine 155 is required for Jab1-mediated nuclear export of p53. BMB Rep. 2017;50(7):373\u20138.","journal-title":"BMB Rep."},{"issue":"1","key":"758_CR24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/15384047.2014.986997","volume":"16","author":"P Gomez-Bougie","year":"2015","unstructured":"Gomez-Bougie P, Halliez M, Ma\u00efga S, Godon C, Kervoelen C, Pellat-Deceunynck C, et al. Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. Cancer Biol Ther. 2015;16(1):60\u20135.","journal-title":"Cancer Biol Ther."},{"issue":"5","key":"758_CR25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.23159","volume":"87","author":"T Golombick","year":"2012","unstructured":"Golombick T, Diamond T, Manoharan A, Ramakrishna R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. Am J Hematol. 2012;87(5):455\u201360.","journal-title":"Am J Hematol."},{"issue":"4","key":"758_CR26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ccr3.2735","volume":"8","author":"R Ramakrishna","year":"2020","unstructured":"Ramakrishna R, Diamond T, Alexander W, Manoharan A, Golombick T. Use of curcumin in multiple myeloma patients intolerant of steroid therapy. Clin Case Rep. 2020;8(4):739\u201344.","journal-title":"Clin Case Rep."},{"issue":"3","key":"758_CR27","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.21873\/anticanres.13225","volume":"39","author":"G Bolger","year":"2019","unstructured":"Bolger G, Licollari A, Bagshaw R, Tan A, Greil R, Vcelar B, et al. Intense uptake of liposomal curcumin by multiple myeloma cell lines: comparison to normal lymphocytes, red blood cells and chronic lymphocytic leukemia cells. Anticancer Res. 2019;39(3):1161\u20138.","journal-title":"Anticancer Res."},{"issue":"4","key":"758_CR28","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00280-018-3654-0","volume":"82","author":"R Greil","year":"2018","unstructured":"Greil R, Greil-Ressler S, Weiss L, Schonlieb C, Magnes T, Radl B, et al. A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (LipocurcTM) in patients with locally advanced or metastatic cancer. Cancer Chemother Pharmacol. 2018;82(4):695\u2013706.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"14","key":"758_CR29","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1182\/blood-2011-01-333138","volume":"118","author":"K Sakakibara","year":"2011","unstructured":"Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman J, et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011;118(14):3922\u201331.","journal-title":"Blood"},{"issue":"Suppl 5","key":"758_CR30","doi-asserted-by":"crossref","first-page":"v175","DOI":"10.1093\/annonc\/mdz244.028","volume":"30","author":"J Wang","year":"2019","unstructured":"Wang J, Barve M, Chiorean E, LoRusso P, Courtney K, Qi D, et al. Interim results from trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumours. Ann Oncol. 2019;30(Suppl 5):v175.","journal-title":"Ann Oncol."},{"issue":"11","key":"758_CR31","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10822-012-9611-9","volume":"26","author":"O Kalid","year":"2020","unstructured":"Kalid O, Warshaviak DT, Shechter S, Sherman W, Shacham S. Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors. J Comput Aided Mol Des. 2020;26(11):1217\u201328.","journal-title":"J Comput Aided Mol Des."},{"issue":"7","key":"758_CR32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","volume":"15","author":"K Parikh","year":"2014","unstructured":"Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)\u2013a novel class of anti-cancer agents. J Hematol Oncol. 2014;15(7):78.","journal-title":"J Hematol Oncol."},{"key":"758_CR33","first-page":"139","volume":"1","author":"M Sendino","year":"2018","unstructured":"Sendino M, Omaetxebarria M, Rodriguez J. Hitting a moving target: inhibition of the nuclear export receptor XPO1\/CRM1 as a therapeutic approach in cancer. Cancer Drug Resist. 2018;1:139\u201363.","journal-title":"Cancer Drug Resist."},{"issue":"8","key":"758_CR34","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/jca.7080","volume":"4","author":"JG Turner","year":"2013","unstructured":"Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, et al. CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo. J Cancer. 2013;4(8):614\u201325.","journal-title":"J Cancer."},{"issue":"1","key":"758_CR35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/1535-7163.MCT-15-0488","volume":"15","author":"S Rosebeck","year":"2016","unstructured":"Rosebeck S, Alonge M, Kandarpa M, Mayampurath A, Volchenboum S, Jasielec J, et al. Synergistic myeloma cell death via novel intracellular activation of caspase-10-dependent apoptosis by carfilzomib and selinexor. Mol Cancer Ther. 2016;15(1):60\u201371.","journal-title":"Mol Cancer Ther."},{"issue":"1","key":"758_CR36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-016-0304-z","volume":"9","author":"JG Turner","year":"2016","unstructured":"Turner JG, Dawson JL, Grant S, Shain K, Dalton W, Dai Y, et al. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol. 2016;9(1):73.","journal-title":"J Hematol Oncol."},{"issue":"48","key":"758_CR37","doi-asserted-by":"crossref","first-page":"78896","DOI":"10.18632\/oncotarget.12969","volume":"7","author":"JG Turner","year":"2016","unstructured":"Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer A, Grant S, et al. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I\u03baB\u03b1 and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. 2016;7(48):78896\u2013909.","journal-title":"Oncotarget."},{"issue":"4","key":"758_CR38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.tranon.2017.04.010","volume":"10","author":"B Muz","year":"2017","unstructured":"Muz B, Azab F, de la Puente P, Landesman Y, Zab AK. Selinexor overcomes hypoxia-induced drug resistance in multiple myeloma. Transl Oncol. 2017;10(4):632\u201340.","journal-title":"Transl Oncol."},{"issue":"1","key":"758_CR39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28(1):155\u201365.","journal-title":"Leukemia"},{"issue":"39","key":"758_CR40","doi-asserted-by":"crossref","first-page":"25529","DOI":"10.18632\/oncotarget.25368","volume":"9","author":"C Argueta","year":"2018","unstructured":"Argueta C, Kashyap T, Klebanov B, Unger T, Guo C, Harrington S, et al. Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death. Oncotarget. 2018;9(39):25529\u201344.","journal-title":"Oncotarget."},{"issue":"8","key":"758_CR41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl D, Gavriatopoulou M, Nooka A, Yee A, Huff C, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727\u201338.","journal-title":"N Engl J Med."},{"issue":"12","key":"758_CR42","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1093\/annonc\/mdq149","volume":"21","author":"MS Aapro","year":"2010","unstructured":"Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol. 2010;21(12):2316\u201323.","journal-title":"Ann Oncol."},{"issue":"Suppl 15","key":"758_CR43","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/JCO.2020.38.15_suppl.8501","volume":"38","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Delimpasi S, Simonova M, Spicka I, Ludek P, Kryachok I, et al. Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: initial results of the phase III BOSTON study. J Clin Oncol. 2020;38(Suppl 15):8501.","journal-title":"J Clin Oncol."},{"key":"758_CR44","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bjh.16550","volume":"189","author":"A Chari","year":"2020","unstructured":"Chari A, Vogl D, Jagannath S, Jasielec J, Unger T, DeCastro A, et al. Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020;189:126\u201330.","journal-title":"Br J Haematol."},{"issue":"4","key":"758_CR45","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjh.15969","volume":"186","author":"AJ Jakubowiak","year":"2019","unstructured":"Jakubowiak AJ, Jasielec J, Rosenbaum CA, Cole CE, Chari A, Mikael J, et al. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed\/refractory multiple myeloma. Br J Haematol. 2019;186(4):549\u201360.","journal-title":"Br J Haematol."},{"key":"758_CR46","doi-asserted-by":"crossref","unstructured":"Chen C, Gasparetto C, White D, Kotb R, Lipe B, Sutherland H, et al. Selinexor, pomalidomide, and dexamethaspone (SPD) in patients with relapsed or refractory multiple myeloma. EHA 24 Abstract PF587. 2019.","DOI":"10.1097\/01.HS9.0000560636.62389.3a"},{"key":"758_CR47","unstructured":"Jei J. Antegene Corporation Treating Patients Without Borders. Business Confidential. 2019. https:\/\/www.jefferies.com\/CMSFiles\/Jefferies.com\/files\/Antengene%20Corporation%20v3.pdf. Accessed 15 Sept 2020."},{"key":"758_CR48","doi-asserted-by":"crossref","unstructured":"White D, LeBlanc R, Venner C, Bahlis N, Lentzsch S, Gasparetto C, et al. Safety and efficacy of the combination of selinexor, lenalidomide and dexamethasone (SRd) in patients with relapsed\/refractory multiple myeloma (RRMM) [abstract no. 3532019]. In: Presented at the 17th International Myeloma Workshop; 12\u201315 Sep 2019: Boston, MA.","DOI":"10.1016\/j.clml.2019.09.084"},{"issue":"Suppl 15","key":"758_CR49","doi-asserted-by":"crossref","first-page":"8510","DOI":"10.1200\/JCO.2020.38.15_suppl.8510","volume":"38","author":"C Gasparetto","year":"2020","unstructured":"Gasparetto C, Lentzsch S, Gary J, Callander N, Tuchman S, Bahlis N, et al. Selinexor, daratumumab, and dexamethasone in patients with relapsed\/refractory multiple myeloma (MM). J Clin Oncol. 2020;38(Suppl 15):8510.","journal-title":"J Clin Oncol."},{"issue":"Suppl 15","key":"758_CR50","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1200\/JCO.2020.38.15_suppl.8530","volume":"38","author":"C Gasparetto","year":"2020","unstructured":"Gasparetto C, Lipe B, Tuchman S, Callander N, Lentzsch S, Baljevic M, et al. Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed\/refractory multiple myeloma (MM). J Clin Oncol. 2020;38(Suppl 15):8530.","journal-title":"J Clin Oncol."},{"issue":"12","key":"758_CR51","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/leu.2016.136","volume":"30","author":"ZA Hing","year":"2016","unstructured":"Hing ZA, Fung HY, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, et al. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. Leukemia. 2016;30(12):2364\u201372.","journal-title":"Leukemia"},{"issue":"23","key":"758_CR52","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.V126.23.1818.1818","volume":"126","author":"J Turney","year":"2015","unstructured":"Turney J, Dawson J, Cubitt C, Baluglo E, Grant S, Dai Y, et al. Next generation XPO1 inhibitor KPT-8602 for the treatment of drug-resistant multiple myeloma. Blood. 2015;126(23):1818.","journal-title":"Blood"},{"key":"758_CR53","unstructured":"Karyopharm Presents Positive Phase 1\/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting [news release]. 2017. https:\/\/investors.karyopharm.com\/news-releases\/news-release-details\/karyopharm-presents-positive-phase-12-eltanexor-data-american. Accessed 15 Sept 2020."},{"issue":"5","key":"758_CR54","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548\u201367.","journal-title":"Am J Hematol."},{"issue":"4","key":"758_CR55","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clml.2013.12.015","volume":"14","author":"K Kortuem","year":"2014","unstructured":"Kortuem K, Zidich K, Schuster S, Khan M, Jimenez-Zepeda V, Mikhael J, et al. Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma. Clin Lymph Myeloma Leuk. 2014;14(4):284\u201390.","journal-title":"Clin Lymph Myeloma Leuk."},{"issue":"26","key":"758_CR56","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1200\/JCO.2016.67.6346","volume":"34","author":"M Gounder","year":"2016","unstructured":"Gounder M, Zer A, Tap W, Salah S, Dickson M, Gupta A, et al. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol. 2016;34(26):3166\u201374.","journal-title":"J Clin Oncol."},{"issue":"34","key":"758_CR57","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","volume":"34","author":"AR Abdul Razak","year":"2016","unstructured":"Abdul Razak AR, Mau-Soerensen M, Gabrail NY, et al. First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34(34):4142\u201350.","journal-title":"J Clin Oncol."},{"key":"758_CR58","unstructured":"US FDA. FDA approves selinexor for relapsed\/refractory diffuse large B-cell lymphoma. 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma. Accessed 15 Sept 2020."},{"issue":"Suppl 15","key":"758_CR59","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.2019.37.15_suppl.2005","volume":"37","author":"A Lassman","year":"2019","unstructured":"Lassman A, Wen P, Bent V, Plotkin S, Walenkamp A, Huang X, et al. Efficacy and safety of selinexor in recurrent glioblastoma. J Clin Oncol. 2019;37(Suppl 15):2005.","journal-title":"J Clin Oncol."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-020-00758-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:07:54Z","timestamp":1744715274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-020-00758-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["758"],"URL":"https:\/\/doi.org\/10.1007\/s11523-020-00758-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]},"assertion":[{"value":"19 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nicholas Theodoropoulos and Guido Lancman declare they have no conflicts of interest. Ajai Chari reports research support from Janssen, Celgene, Novartis Pharmaceuticals, Amgen, Pharmacyclics, Seattle Genetics, and Millenium\/Takeda, and also reports consulting fees from Janssen, Celgene, Novartis Pharmaceuticals, Amgen, BMS, Karyopharm, Sanofi Genzyme, Seattle Genetics, Oncopeptides, Millenium\/Takeda, Antengene, GlaxoSmithKline, and Secura Bio.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}